0001062993-24-008676.txt : 20240423 0001062993-24-008676.hdr.sgml : 20240423 20240423125511 ACCESSION NUMBER: 0001062993-24-008676 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240422 FILED AS OF DATE: 20240423 DATE AS OF CHANGE: 20240423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EVOME MEDICAL TECHNOLOGIES INC. CENTRAL INDEX KEY: 0001617765 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-255642 FILM NUMBER: 24863594 BUSINESS ADDRESS: STREET 1: SUITE 2700, STREET 2: 1133 MELVILLE STREET CITY: VANCOUVER STATE: A1 ZIP: V6E 4E5 BUSINESS PHONE: 800-760-6826 MAIL ADDRESS: STREET 1: SUITE 2700, STREET 2: 1133 MELVILLE STREET CITY: VANCOUVER STATE: A1 ZIP: V6E 4E5 FORMER COMPANY: FORMER CONFORMED NAME: Salona Global Medical Device Corp DATE OF NAME CHANGE: 20210111 FORMER COMPANY: FORMER CONFORMED NAME: INSPIRA FINANCIAL INC DATE OF NAME CHANGE: 20140825 6-K 1 form6k.htm FORM 6-K Evome Medical Technologies Inc.: Form 6-K - Filed by newsfilecorp.com

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of April 2024

Commission File Number: 333-255642

EVOME MEDICAL TECHNOLOGIES INC.

(Translation of registrant's name into English)

49 Natcon Drive, Shirley, New York 11967, United States

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. 

Form 20-F ☒  Form 40-F ☐

FOREIGN PRIVATE ISSUER STATUS

Evome Medical Technologies Inc. (the “Company,” “our” or “we”) has qualified as a “foreign private issuer” as defined in Rule 405 under ‎the U.S. Securities Act of 1933, as amended, and Rule 3b-4 under the U.S. Securities Exchange Act of ‎‎1934, as amended (the “Exchange Act”).  As a result, with respect to our future reports filed with the Securities and Exchange Commission (“SEC”), we intend to report on forms available to foreign private issuers.

For so long as we are a foreign private issuer, we are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we will have four months after the end of each fiscal year to file our annual reports with the SEC and will not be required to file current reports as frequently or promptly as U.S. domestic reporting companies.  These exemptions and leniencies, along with other corporate governance exemptions resulting from our ability to rely on home country rules, will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic reporting companies.  If we were to lose our foreign private issuer status, the regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer will be significantly more than costs we incur as a foreign private issuer.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  EVOME MEDICAL TECHNOLOGIES INC.
   
   
Date:  April 22, 2024 By:  /s/ Michael Seckler                            
  Name: Michael Seckler
  Title: Chief Executive Officer